Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol

Journal of Gene Medicine

Volumn 6, Issue 9, 2004, Pages 963-973

  Lu, Xiaobin ^a   Humeau, Laurent ^a   Slepushkin, Vladimir ^a   Binder, Gwendolyn ^a   Yu, Qiao ^a   Slepushkina, Tatiana ^a   Chen, Ziping ^a   Merling, Randall ^a   Davis, Brian ^a   Chang, Yung Nien ^a   Dropulic, Boro ^a,b  

^a VIRxSYS Corporation   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antisense payload; Cis ribozyme; High efficiency transduction; HIV 1; Lentiviral vector

Indexed keywords

CD4 ANTIGEN; CIS ACTING ELEMENT; GAG PROTEIN; LENTIVIRUS VECTOR; POL PROTEIN; RIBOZYME; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL BASED GENE THERAPY; CONTROLLED STUDY; GENE EXPRESSION; GENE INSERTION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PLASMID; PLASMID VRX496; PRIORITY JOURNAL; RISK REDUCTION; RNA TRANSLATION; SAFETY; SCID MOUSE; SEQUENCE HOMOLOGY; T LYMPHOCYTE; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; ANTISENSE ELEMENTS (GENETICS); CELLS, CULTURED; GENE PRODUCTS, ENV; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HIV-1; HUMANS; LENTIVIRUS; MICE; MICE, SCID; PLASMIDS; RNA, CATALYTIC; RNA, VIRAL; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VIRAL PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

EID: 20844445774     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.593     Document Type: Article

References (38)

1. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413.
2. Hacein-Bey-Abina S, Fischer A, Cavazzana-Calvo M. Gene therapy of X-linked severe combined immunodeficiency. Int J Hematol 2002; 76: 295-298.
3. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 2002; 270: 475-480.
4. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
5. Zaiss A-K, Son S, Chang L-J. RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for safety and efficacy. J Virol 2002; 76: 7209-7219.
6. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HfV-1 infection. Nature 1997; 387: 183-188.
7. Herndier BG, Shiramizu BT, Jewett NE, Aldape KD, Reyes GR, McGrath MS. Acquired immunodeficiency syndrome-associated T-cell lymphoma: evidence for human immunodeficiency virus type 1-associated T-cell transformation. Blood 1992; 79: 1768-1774.
8. Rouzine IM, Coffin JM. Search for the mechanism of genetic variation in the pro gene of human immunodeficiency virus. J Virol 1999; 73: 8167-8178.
9. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. (1996). Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 1996; 93: 11 382-11 388.
10. VandenDriessche T, Thorrez L, Naldini L, et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002; 100: 813-822.
11. Sirven AL, Pflumio F, Zennou V, et al. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral nuclear import and gene transduction of human hematopoetic cells. Blood 2000; 96: 4103-4110.
12. Trono D, Feinberg MB, Baltimore D. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989; 59: 113-120.
13. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
14. Lotti F, Menguzzato E, Rossi C, et al. Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement. J Virol 2002; 76: 3996-4007.
15. Kafri T, van Praag H, Gage FH, Verma IM. Lentiviral vectors: regulated gene expression. Mol Ther 2000; 1: 516-521.
16. Xu K, Ma H, McCown TJ, Verma IM, Kafri T. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther 2001; 3: 97-104.
17. Pfeifer A, Brandon EP, Kootstra N, Gage FH, Verma IM. Delivery of the cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. Proc Natl Acad Sci U S A 2001; 98: 11450-11455.
18. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2001; 101: 173-185.
19. Poznansky M, Lever A, Bergeron L, Haseltine W, Sodroski J. Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector. J Virol 1991; 65: 532-536.
20. Dropulic B, Hermanokova M, Pitha PM. A conditionally replicating HIV-1 vector interferes with wild type HIV-1 replication and spread. Proc Natl Acad Sci U S A 1996; 93: 11103-11108.
21. Schroers R, Davis CM, Wagner H-J, Chen S-Y. Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection. Gene Ther 2002; 9 889-897.
22. Mautino MR, Morgan RA. Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA. Hum Gene Ther 2002; 13: 1027-1037.
23. Dropulic B, Jeang K-T. A virus model for examining the intracellular efficiency of a ribozyme targeted to HrV-1. Methods Enzymol 1993; 5: 43-49.
24. Available: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3794b3.htm.
25. MacGregor RR. Clinical protocol. A phase I open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects. Hum Gene Ther 2001; 12: 2028-2029.
26. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986; 59: 284-291.
27. Slepushkin V, Chang N, Cohen R, et al. Large-scale purification of a lentiviral vector by size exclusion chromatography or mustang Q ion exchange capsule. Bioproc J 2003; Sep/Oct: 89-95.
28. Schonely K, Afable C, Slepushkin V, et al. QC release testing of an HIV-1 based lentiviral vector lot and transduced cellular product. Bioproc J 2003; Jul/Aug: 39-47.
29. Ikeda Y, Tekeuchi Y, Martin F, Cosset FL, Mitrophanous K, Collins M. Continuous high-titer HIV-1 vector production. Nat Biotechnol 2002; 21: 569-572.
30. Haseloff J, Gerlach WL. Sequences required for self-catalysed cleavage of the satellite RNA of tobacco ringspot virus. Gene 1989; 82: 43-52.
31. Humeau L, Binder G, Lu X, et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 T lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther; in press.
32. Lu X, Yu Q, Binder G, et al. Antisense-mediated inhibition of HIV replication using an HIV-1-based vector results in severely attenuated mutants incapable of developing resistance. J Virol 2004; in press.
33. Manganini M, Serafini M, Barnbacioni F, et al. A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors. Hum Gene Ther 2002; 13 1793-1807.
34. Costello E, Munoz M, Buetti E, Meylan PRA, Diggelmann H, Thali M. Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. Gene Ther 2000; 7: 596-604.
35. Ranga U, Woffendin C, Verma S, et al. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A 1998; 95: 1201-1206.
36. + T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96: 785-792.
37. Follenzi A, Ailles LE, Bakovic S, Genua N, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25: 217-222.
38. Cavalieri S, Cazzaniga S, Geuna M, et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR-activation maintain an intact immune competence. Blood 2003; 102: 497-505.